Weight Loss Treatment
29,90 €
Weight Loss Treatment29,90 €
Weight Loss TreatmentThis page is for you if excess weight comes together with type 2 diabetes, high blood pressure or raised cholesterol and you want to know whether a weight management medicine could be added to your treatment. It explains the criteria in the product information, what the doctor checks against your other conditions and medicines, when the answer is a visit in person, and what the review costs.
Type 2 diabetes, high blood pressure (hypertension) and raised blood fats (dyslipidaemia) are named in the product information of the weight management medicines as weight-related conditions. This matters because they lower the body mass index (BMI) at which treatment can be considered: without such a condition, the threshold is a BMI of 30 or more; with at least one of them, it starts at 27 for most of these medicines.
BMI is your weight in kilograms divided by the square of your height in metres. A person 1.70 m tall who weighs 80 kg has a BMI of about 27.7, which falls in the band of 27 to below 30. Treatment with semaglutide, tirzepatide or liraglutide goes hand in hand with a reduced-calorie diet plus more physical activity; with orlistat, the diet is mildly reduced in calories. Each is added to the treatment of your other conditions, not used in place of it.
The table summarises section 4.1 of the product information for four substances used for weight management in adults, and how each is taken. All four are medicines subject to medical prescription under their EU product information (Annex II B).
| Substance | How it is taken | Adults it is authorised for | When section 4.1 says to stop |
|---|---|---|---|
| Semaglutide | Injection once a week; also authorised as a tablet once a day | BMI of 30 or more, or from 27 to below 30 plus at least one weight-related condition, for example hypertension, prediabetes, dyslipidaemia, cardiovascular disease, type 2 diabetes or obstructive sleep apnoea | None stated for adults |
| Tirzepatide | Injection once a week | BMI of 30 or more, or from 27 to below 30 plus at least one weight-related condition (cardiovascular disease, hypertension, type 2 diabetes, prediabetes, dyslipidaemia or obstructive sleep apnoea, for example) | None stated for adults |
| Liraglutide | Injection once a day | BMI of 30 or more, or from 27 to below 30 together with a weight-related condition (at least one), for example type 2 diabetes, dyslipidaemia, prediabetes, obstructive sleep apnoea or hypertension | When weight loss is below 5% of the starting weight after 12 weeks on 3.0 mg daily |
| Orlistat 120 mg | One capsule with each main meal; left out if the meal contains no fat | BMI 30 or more, or over 28 where associated risk factors are present | After 12 weeks, if less than 5% of the starting weight has been lost |
A single tirzepatide product carries both authorisations, one for type 2 diabetes and one for weight management, whereas for semaglutide, type 2 diabetes is covered by separate products. If you already take one of these substances for your diabetes, tell the doctor which product and which dose: the product information for semaglutide says it should not be combined with another medicine of the same class.
Several warnings in the product information concern people with diabetes. The first is low blood sugar (hypoglycaemia): insulin and sulfonylureas such as gliclazide can cause it, and the risk rises when semaglutide, tirzepatide or liraglutide is added. The product information says the risk can be lowered by reducing the dose of the insulin or sulfonylurea. That change is planned by whoever manages your diabetes, so the doctor may ask who that is and how your treatment is set up.
The second warning concerns the eyes. A rapid improvement in blood sugar has been associated with a temporary worsening of diabetic retinopathy, so retinopathy needs close monitoring; for semaglutide, treatment is not recommended if retinopathy is uncontrolled or potentially unstable. Semaglutide and liraglutide are not substitutes for insulin, and semaglutide has not been studied in type 1 diabetes.
With liraglutide, diabetic ketoacidosis has been reported in people who depend on insulin after their insulin was stopped quickly or its dose was reduced. For orlistat, the product information says that diabetes treatment may need close monitoring.
More about the other medicines for type 2 diabetes, such as metformin, is on our page on type 2 diabetes and blood sugar medicines.
Hypertension, dyslipidaemia and cardiovascular disease are among the weight-related conditions named in section 4.1, so they can bring the BMI threshold down to 27. The weight management medicine is added to your blood pressure and cholesterol treatment. Do not stop or change those medicines on your own because you have started it; any change is a decision for the doctor who prescribes them, based on your measurements.
The product information points to two things that matter here. Nausea, vomiting and diarrhoea can lead to dehydration, which in rare cases worsens kidney function, so you are advised to drink enough and avoid losing fluids; this needs particular care if your kidneys are already affected. Tirzepatide also slows the emptying of the stomach, which can change how quickly tablets are absorbed, and its product information recommends monitoring of medicines with a narrow therapeutic range, such as warfarin or digoxin, at the start and after a dose increase.
Orlistat has its own list: oral anticoagulants need monitoring of blood clotting, it is not recommended with ciclosporin, it may weaken the control of an underactive thyroid treated with levothyroxine, and it can reduce the absorption of medicines for epilepsy. Blood pressure medicines and statins are described on our page on high blood pressure and our page on statins and cholesterol medicines.
Your answers go into a medical questionnaire, which asks about the medicine, about your health and about the other medicines you are taking. The doctor reads your answers against the product information and may ask, in writing, for more. These are the points that usually shape the decision when weight comes together with a long-term condition.
Nausea, vomiting, diarrhoea and constipation are listed as very common with semaglutide, tirzepatide and liraglutide. The product information describes them as mostly mild to moderate; for liraglutide they usually occur in the first weeks of treatment, and for tirzepatide they are more frequent while the dose is being increased. Gallstones appear among the listed side effects of all three, and acute pancreatitis has been reported. The package leaflet for semaglutide says that severe, ongoing pain in the stomach area needs a doctor without delay, because it can be a sign of an inflamed pancreas.
With semaglutide, epidemiological studies indicate an increased risk of an eye condition called non-arteritic anterior ischaemic optic neuropathy (NAION); a sudden loss of vision needs an eye examination. Orlistat works differently: it blocks the enzymes that digest fat in the gut, and its gastrointestinal side effects are more likely after a meal high in fat. With severe diarrhoea on orlistat, its product information recommends an additional contraceptive method.
In an emergency, call 112. Severe abdominal pain, signs of dehydration or a sudden loss of vision are reasons to see a doctor in person without delay, or to go to Accident and Emergency.
The product information for semaglutide and for tirzepatide recommends contraception for women who could become pregnant during treatment, and both substances are stopped if you wish to become pregnant or become pregnant. Because they stay in the body for a long time, semaglutide is stopped at least 2 months and tirzepatide at least 1 month before a planned pregnancy. Semaglutide is not used while breastfeeding.
Liraglutide is not used in pregnancy or while breastfeeding, and it is stopped if you wish to become pregnant or become pregnant. For orlistat, the product information advises caution in pregnancy, and breastfeeding is a contraindication.
For tirzepatide, a study with a combined pill found a fall in hormone levels after a single dose, which the product information does not consider clinically relevant; it requires no change in the dose of the pill. Choosing or continuing a method is covered on our page on the contraceptive pill.
For some conditions, and in some individual cases, it is advisable to see a doctor in person; the doctor may recommend this. When several long-term conditions are treated at once, starting a weight management medicine can mean that other treatment needs adjusting at the same time, and that is easier to plan with the doctor who already looks after you. In individual cases the doctor may decline or recommend a visit in person, for example with the situations below.
If the doctor issues a prescription, you receive it as a PDF by email. You print it and bring it on paper to a pharmacy in Malta together with photo identification. Your prescription is issued in the standard EU cross-border format set out in Directive 2012/52/EU. A pharmacy in Malta may dispense it; the decision rests with the pharmacist.
Take the prescription to a pharmacy within six months of the date on it; a prescription for an antibiotic cannot be dispensed more than ten days after its date of issue. It is not an ePrescription and does not appear in myHealth; it is outside POYC and the Government Formulary List, and you pay for the medicine at the pharmacy in full.
For a review in the Weight Loss Treatment service, the fee is 29,90 €. The fee covers the medical consultation, not the issuing of a document. If the doctor declines on medical or legal grounds, we refund the fee. If the doctor asks you for documents, you have at least 7 days to send them in and we send you a reminder; if you ask us, we agree a longer deadline. If the case still cannot be completed, we close the request, let you know and refund the fee in full.
For 9,90 € more, priority handling lifts your request higher in the doctor's queue, but it carries no promise of a time. The medicine is a separate cost at the pharmacy; we do not sell medicines.
Requests in this service are handled by Damian Wojno, a doctor registered with the Polish Medical Chamber, licence no. 3211301. If the doctor has questions, they ask them in writing in the chat in your account, and you get an email to let you know. There is no video call, no phone call and no live chat. In the course of the review, the doctor might want records, test results or a measurement such as your blood pressure, might advise you to see a doctor in Malta, and might decline the request. The doctor is not registered with the Medical Council of Malta.
The product information lists type 2 diabetes among the weight-related conditions, so for semaglutide, tirzepatide and liraglutide, treatment may be considered once your BMI reaches 27. Whether it suits you depends on your diabetes medicines, your eyes, your kidneys and your other conditions; the doctor decides after reviewing your answers and may also decline or recommend a visit in person.
Section 4.1 of the product information for semaglutide, tirzepatide and liraglutide covers adults whose BMI is 30 or more, or 27 to below 30 where at least one weight-related condition is present; hypertension and dyslipidaemia are among its examples. For orlistat 120 mg the figures are 30, or above 28 with associated risk factors.
A weight management medicine is added to the treatment of your other conditions. Do not stop or change your diabetes, blood pressure or cholesterol medicines on your own. If you take insulin or a sulfonylurea, the product information says their dose may need reducing to lower the risk of hypoglycaemia, and that change is planned by the doctor who manages your diabetes.
You can request a review whether you are starting or continuing. Tell the doctor the product, your current dose, when you started and how you have responded; the doctor may ask for earlier records or measurements before deciding.
Tell the surgeon or the anaesthetist that you take the medicine. Cases of pulmonary aspiration have been reported in people taking medicines of this class during general anaesthesia or deep sedation, because the stomach empties more slowly, and the product information for semaglutide, tirzepatide and liraglutide asks for this to be considered before such procedures.
A prescription from a doctor in another EU country can be dispensed in Malta (Article 81(3) of the Medicines Act, Cap. 458) if the pharmacist can confirm the doctor's licence. The decision rests with the pharmacist, who may refuse.